Shionogi, Inc.

Shire Laboratories, Inc.

Supernus Pharmaceuticals, Inc.

Glycomimetics, Inc.

Supermus Pharmaceuticals, Inc.

Tcd Royalty Sub, LLC

Henry H Flanner

Beth A Burnside

Colin E Rowlings

Sandra E Wassink

Jill E Pinkett

Edward M Rudnic

Padmanabh P Bhatt

Argaw Kidane

Richard Alan Couch

Arash Raoufinia

Donald Treacy

Susan P Clausen

Robert J Guttendorf

Sanna Tolle-Sander

Rong-Kun Chang

Xiaodi Guo

Scott Ibrahim

Marcus Schestopol

Lisa C McKnight

Rong Kun Chang

Lisa R White

Curt D Wolfgang

Helen M Thackray

Lisa C Mcknight

Methods for treating or inhibiting cancer and/or one or more related conditions by administering to a subject in need thereof an effective amount of a compound of Formula (I), a prodrug thereof, or a pharmaceutically acceptable salt of any of the foregoing. For example, methods for treating AML, MDS, neutropenia, and/or mucositis comprising administering a pharmaceutical composition comprising a compound of Formula (I) are described.

Methods for treating acute myeloid leukemia and related conditions

An antibiotic product is comprised of at least three dosages forms, each of which has a different release profile, with the Cfor the antibiotic product being reached in less than about twelve hours after the initial release of antibiotic. In one embodiment, there is a delayed release dosage form, as well as two or more delayed sustained release dosage forms, with each of the dosage forms having a different release profile, wherein each reaches a Cat different times.

Antibiotic product, use and formulation thereof

Disclosed are pharmaceutical products for providing pulses of at least one pharmaceutically active ingredient from a patient's stomach, or from a subsequent gastrointestinal site proximal thereto, for absorption thereof at a site(s) more distal in the gastrointestinal tract than the patient's stomach, or than the subsequent gastrointestinal site proximal thereto. The product comprises first, second, and third pharmaceutical dosage forms, each of which comprises at least one pharmaceutically active agent and a pharmaceutically acceptable carrier. The product is formulated such that at least two of the first, second, and third pharmaceutical dosage forms further comprise means for providing temporary gastric-retention of the at least two of the first, second, and third pharmaceutical dosage forms within the patient's stomach, or at the subsequent gastrointestinal site proximal thereto.

Gastric release pulse system for drug delivery

An amoxicillin product comprising: at least one modified release component(s), wherein the at least one modified release component(s) comprises at least amoxicillin and a pharmaceutically acceptable carrier; and wherein when administered to a patient or subject in the fed state said amoxicillin product exhibits a pharmacokinetic profile for amoxicillin in the plasma characterized as follows: (1) the ratio of the portion of the AUC as measured from 2 hours post-administration to 5 hours post-administration to the portion of the AUC as measured from administration to 2 hours post-administration is at least 2.0:1; and (2) the ratio of the portion of the AUC as measured from 5 hours post-administration to 12 hours post-administration to the portion of the AUC as measured from administration to 2 hours post-administration is at least 1.1:1.

Modified release amoxicillin products

An antibiotic product is comprised of at least three dosage forms, each of which has a different release profile, with the Cfor the antibiotic product being reached in less than about twelve hours after the initial release of antibiotic. In one embodiment, there are two delayed release dosage forms, as well as a delayed sustained release dosage form, with each of the dosage forms having a different release profile, wherein each reaches a Cat different times.

An antibiotic product is comprised of at least three dosages forms, each of which has a different release profile, with the Cfor the antibiotic product being reached in less than about twelve hours. In one embodiment, there is an immediate release dosage form, as well as two or more sustained release dosage forms, with each of the dosage forms having a different release profile, wherein each reaches a Cat different times.

Disclosed are once-a-day penicillin-type antibiotic products comprising at least one modified release dosage form comprising penicillin-type antibiotics and pharmaceutically acceptable carriers, which compositions provide T&#x3e;MICin the serum for at least 5 hours (preferably for at least five consecutive hours), within a 24-hour dosing interval, for a given bacterial pathogen's MIC, while providing a total dosage of the penicillin-type antibiotic for a 24-hour dosing interval.

Compositions and methods for improved efficacy of penicillin-type antibiotics

An antibiotic product is comprised of at least three dosages forms, each of which has a different release profile, with the Cfor the antibiotic product being reached in less than about twelve hours. In one embodiment, there is an immediate release dosage form, a delayed release dosage form, and a sustained release dosage form, with each of the dosage forms having a different release profile, wherein each reaches a Cat different times.

An antibiotic product is comprised of at least three dosages forms, each of which has a different release profile, with the Cfor the antibiotic product being reached in less than about twelve hours. In one embodiment, there is an immediate release dosage form, a sustained release dosage form, and a delayed release dosage form, with each of the dosage forms having a different release profile, wherein each reaches a Cat different times.

A process for treating a bacterial infection with an antibiotic, comprising: administering to a patient with a bacterial infection a product that includes a modified release dosage form containing an antibiotic, said product being administered once-a-day in a dosage and for a number of days that provides a Total T&#x3e;MIC sufficient to achieve at least the minimum amount of bacterial eradication for treatment of said bacterial infection.

Pharmaceutical compositions and methods for improved bacterial eradication

A pharmaceutical composition of a pharmaceutically acceptable trospium salt, with upon administration to a human patient generates an average steady state blood levels of trospium with a minimum (C) and maximum (C) blood levels of about 0.5-2.5 ng/ml and about 2.0-6.0 ng/ml, respectively.

Growing community of inventors

Montgomery Village, MD, United States of America

Henry H Flanner